Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

BACKGROUND: Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MDR-TB), especially in developing countries where the burden of MDR-TB is highest. Their protracted use in MDR-TB treatment is known to cause dose-dependent irreversible hearing loss, requiring hearing...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Pharmacol Toxicol
Asıl Yazarlar: Sagwa, Evans L., Ruswa, Nunurai, Mavhunga, Farai, Rennie, Timothy, Leufkens, Hubert G. M., Mantel-Teeuwisse, Aukje K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4675035/
https://ncbi.nlm.nih.gov/pubmed/26654443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-015-0036-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller